BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $1.34 · Revenue $1.03B · 11 analysts
Est. EPS $1.14
Est. EPS $1.77 · Revenue $1.13B · 11 analysts
Est. EPS $5.03 · Revenue $3.91B · 16 analysts
EPS $1.23 · Revenue $825.41M
EPS $0.95 · Revenue $745.14M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $3.2B | +12.9% | +29.2% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $348.9M | -18.3% | -57.6% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +77.1% | -3.2% | +6.7% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +16.6% | -2.4% | -33.8% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +10.8% | -27.6% | -67.2% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $725.0M | +52.5% | -30.3% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +22.5% | +35.1% | -46.0% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 10.6% | -8.0% | +186.8% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 5.21x | -2.2% | -58.9% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $7.6B | +8.7% | +36.5% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 1.80 vs 2.21 | -18.5% | 0.23 vs 1.34 | -82.8% |
| Revenue Surprise | $3.2B vs $3.2B | +1.3% | $989.7M vs $1.0B | -3.6% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Davis George Eric | officer: EVP, Chief Legal Officer | Common Stock | D | 17,557 | $66.28 |
| Jun 2, 2026 | Countouriotis Athena | director | Common Stock | A | 7,490 | — |
| Jun 2, 2026 | Walbert Timothy P | director | Common Stock | A | 7,490 | — |
| Jun 2, 2026 | Ho Maykin | director | Common Stock | A | 7,490 | — |
| Jun 2, 2026 | HOMBACH ROBERT J. | director | Common Stock | A | 7,490 | — |
Operator: Good afternoon and welcome everyone to the BioMarin Pharmaceutical Inc. First Quarter 2026 Conference Call. Today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press the star key followed by the number one on your telephone keypad. If you would like to withdraw your question, press star 1 again. At this time, I would like to turn the conference over to Traci McCarty, Head of Investor Relations. Please go ahead. Traci McCarty: Thank you, operator. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin Pharmaceutical Inc.'s financial performance, commercial products, and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of BioMarin Pharmaceutical Inc.'s product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market, and developments by competitors, and those factors detailed in BioMarin Pharmaceutical Inc.'s filings with the Securities and Exchange Commission, such as 10-Q, 10-Ks, and 8-Ks reports. In addition, we will use non-GAAP financial measures as defined in Regulation G during the call today. These non-GAAP measures should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with U.S. GAAP. You can find the related reconciliations to U.S. GAAP in the earnings release and earnings presentation, both of which are now available in the Investor Relations section of our website. Please note that our commentary on today's call will focus on non-GAAP financial measures unless otherwise indicated. Beginning on slide three and introducing BioMarin Pharmaceutical Inc.'s management team, joining today's call are Alexander Hardy, chief executive officer; Brian Mueller, chief financial officer; Cristin Hubbard, chief commercial officer; and Gregory Friberg, chief R&D officer. I will now turn the call over to BioMarin Pharmaceutical Inc.'s President and CEO, Alexander Hardy. Alexander Hardy: Thank you, Traci, and thank you all for joining us today. I am so pleased that we completed the Amicus acquisition last week, starting a new and exciting chapter for BioMarin Pharmaceutical Inc. with the addition of two innovative therapies, Galafold for Fabry disease and Pombility and Opfolda for Pompe disease. The acquisition accelerates our anticipated year-over-year 2026 revenue growth to 20% at the midpoint of today's updated guidance. The strengthening trajectory is just the beginning of BioMarin Pharmaceutical Inc.'s enhanced longer-term financial outlook, supported by our larger, more diversified commercial portfolio. Since …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Alexander Hardy | President, Chief Executive Officer & Director | USD 3,184,624 | Male | 1969 | Active |
George Eric Davis | Executive VP, Chief Legal Officer & Secretary | USD 1,310,611 | Male | 1971 | Active |
Brian R. Mueller | CFO & Executive VP of Finance | USD 1,309,546 | Male | 1974 | Active |
Cristin Hubbard | Executive Vice President & Chief Commercial Officer | USD 1,294,723 | Female | — | Active |
Gregory Friberg | Executive Vice President and Chief Research & Development Officer | USD 1,283,050 | — | — | Active |
C. Greg Guyer | Executive Vice President & Chief Technology Officer | USD 1,272,708 | — | 1962 | Active |
Rashmi Eshwar Ramchandani | VP, Chief Accounting Officer & Principal Accounting Officer | — | Female | 1979 | Active |
Arpit Dave | Executive Vice President, Chief Digital & Information Officer | — | Male | — | Active |
Amy Wireman | Executive Vice President & Chief People Officer | — | Female | — | Active |
Kevin Eggan | Chief Scientific Officer & Senior Vice President of Research and Early Development | — | — | — | Active |
Amundi trimmed its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 4.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 188,536 shares of the biotechnology company's stock after selling 9,047 shares during the period. Amundi owned approximately
SAN RAFAEL, Calif., July 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m.
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ReNU syndrome was discovered in 2024 and there are no medicines approved for the condition Collaboration combines BioMarin's leadership in genetic medicines with n-Lorem's pioneering antisense expertise Investigational antisense oligonucleotide (ASO) aims to address the underlying genetic cause of this serious neurodevelopmental condition SAN RAFAEL, Calif. and SAN DIEGO, July 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and n-Lorem Foundation, a nonprofit organization, today announced a strategic collaboration and global exclusive license agreement to develop a first-in-disease, antisense oligonucleotide (ASO) medicine for people living with ReNU syndrome, a serious and rare neurodevelopmental condition caused by variants in the RNU4-2 gene.
Bank of New York Mellon Corp decreased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 35.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,144,892 shares of the biotechnology company's stock after selling 631,362
